The company also announced a KOL event scheduled for December 11, 2025, which may provide additional insights into the clinical development program. According to the earnings call transcript, CEO ...
Cinclus Pharma Holding AB (CINPHA) presented its Q3 2025 results on November 20, 2025, highlighting progress in its clinical development program for Linaprazan glurate, a next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback